|   | | | |
Location:检索结果
专利查询
 
  检索记录: 420   总页数: 9   用时: 3.844秒
授权号 公开日 国际主分类 美国主分类 申请人 发明人 优先权
  
 每页条数 50 100 200    9 3 4 :      跳至 页           返回
全部    个人申请    机构申请    跨境申请
  公开号
发明名称
申请人
  1  TW201336995
旭化成化學股份有限公司;
       本發明提供從葡萄糖等便宜且普遍存在之原料,以一階段之步驟即可生產鯊肌醇之工業性製造方法。另,提供經由該製造方法獲得之新穎鯊肌醇衍生物。本發明之鯊肌醇係經由保有肌醇-1-磷酸合成酶基因、肌醇單磷酸酯酶基因、肌肉肌醇脫氫酶基因及鯊肌醇脫氫酶基因之轉形微生物,以一階段從葡萄糖發酵生產者。經由該發酵,亦提供與葡萄糖等糖類結合之鯊肌醇衍生物。

  2  TW201333205
旭化成化學股份有限公司;
       【課題】適用於基因重組技術及合成生物學的方法,對於大腸菌等未具有內因性肌肉肌醇生合成路徑之宿主微生物賦予顯著改善之肌肉肌醇生產能。【解決方法】在未具有內因性肌肉肌醇生合成路徑之宿主微生物內導入肌肉肌醇生合成路徑獲得之形質轉化體,強化肌醇單磷酸酶活性。

ASAHI KASEI CHEMICALS CORPORATION
       (EN)[Problem] To impart significantly improved myo-inositol producing capability, suitable for use in recombinant DNA techniques and synthetic biology methods, to a host microorganism that does not possess an endogenous myo-inositol biosynthesis pathway, such as Escherichia coli. [Solution] Inositol monophosphatase activity is strengthened in a transformant obtained by introducing a myo-inositol biosynthesis pathway into a host microorganism that does not possess an endogenous myo-inositol biosynthesis pathway.
(FR)Le problème décrit par l'invention concerne le fait d'offrir une capacité de production de myo-inositol significativement améliorée, appropriée pour une utilisation dans des techniques d'ADN recombinant et des procédés de biologie synthétique, à un microorganisme hôt

  4  EP2578594
SANOFI SA
       The present invention relates to a process of preparation of L-iduronic acid and derivatives comprising a decarboxylation/intramolecular cyclisation tandem reaction. The present invention also relates to the intermediates of the process, as well as their use as intermediates in the preparation of Idraparinux.

CHEPURI, RAMANA VENKATA;
       (EN)Disclosed herein is 10-α/β-D-Arabinofuranosylundecenes of general Formula (II) or pharmaceutically acceptable salts thereof as anti-mycobacterial agents in vitro; (II) wherein R, R1 and R" are as defined herein in the specification. The present invention also discloses a simple stereoselective synthesis 10-α/β-D-Arabinofuranosylundecenes of Formula (II) to target enzymes involved in the biosynthesis of cell wall of Mycobacterium and thus useful as inhibitors in the Mycobacterium tuberculosis drug development.
(FR)La présente invention concerne des 10-α/β-D-arabinofuranosylundécènes de formule générale (II), et leurs sels de qualité pharmaceutique, utiles comme agents anti-mycobactériens in vitro ; (II) où R, R1 et R" sont définis dans le mémoire. La présente invention concerne éga

NANJING UNIVERSITY OF TECHNOLOGY;
       (EN)Provided are a fructosylated mangiferin, a preparation method therefor and a use thereof, wherein the fructosylated mangiferin has a structural formula represented by the following formula (I), the method for preparing the fructosylated mangiferin includes adding a substance with fructosylating enzymatic activity to a transformation liquid containing mangiferin for biotransformation reaction, so as to convert the mangiferin into the fructosylated mangiferin, wherein the transformation liquid contains the mangiferin and a glycosyl donor; as well as a use of the fructosylated mangiferin in preparation of a medicament for treatment of tumor-related diseases.
(FR)L'invention concerne une mangiférine fructosylée, son procédé de préparation et son utilisation, la mangiférine fructosylée

TURUN YLIOPISTO;
       (EN)This invention relates to synthetic oligo- or multivalent beta- 1 - 2 - linked mannooligosaccharide compounds and to their use for modulating T helper (Th) and T regulatory (Treg) cell -mediated immune responses.
(FR)Cette invention concerne des composés synthétiques mannooligosaccharides β-1-2-liés oligo- ou multivalents et leur utilisation pour la modulation de réponses immunitaires à médiation par des lymphocytes T auxiliaires (Th) et lymphocytes T régulateurs (Treg).

  8  HK1164324
陶氏益農公司 美國/美利堅合眾國 DOW AGROSCIENCES LLC 9330 ZIONSVILLE ROAD INDIANAPOLIS, IN 46268-1054 UNITED STATES/UNITED STATES OF AMERICA
       摘要適用於:CN102388059
本說明書公開的發明涉及殺蟲劑領域和它們在防治害蟲中的用途。本發明公開了具有式(I)的化合物。

  9  HK1164325
陶氏益農公司 美國/美利堅合眾國 DOW AGROSCIENCES LLC 9330 ZIONSVILLE ROAD INDIANAPOLIS IN 46268-1054 UNITED STATES/UNITED STATES OF AMERICA
       摘要適用於:CN102388058
本說明書公開的發明涉及殺蟲劑領域和它們在防治害蟲中的用途。本發明公開了具有以下結構的化合物。

  10  JP2012517475
DOW AGROSCIENCES LLC;
       The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the structure (I) is disclosed.

  11  WO2012093091
DEUTSCHES KREBSFORSCHUNGSZENTRUM;
       (EN)The present invention relates to saccharide mimics which show a better biological activity at low concentrations as known saccharide mimics in inhibiting angiogenesis and inhibiting formation of metastasis by inhibiting adhesion and/or migration of human cancer cells, particularly in concentrations lower than 5 mM, and to pharmaceutical compositions comprising these saccharide mimics. The compounds of the present invention are useful as mimics of cell surface structures and, thus, for influencing cell-cell and cell-extracellular (ECM) interactions, which are controlled by bonds between protein-protein, saccharide-saccharide or saccharide-lectin on the cell-surface.
(FR)La présente invention concerne des analogues de glucides qui, à faibles concentrations, présentent une meilleure

TOYO SUISAN KAISHA, LTD.;
       Provided are a novel compound which is retained specifically in a tumor, a method for retaining the compound in a tumor, and a method for detecting, diagnosing and treating a tumor using the same. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof.腫瘍に特異的に滞留する新規化合物、それを腫瘍に滞留させる方法、それを用いた腫瘍を検出、診断および治療する方法を提供する。本発明は、式(I)の化合物またはその薬学的に許容される塩に関する:
【化a】
イメージ ID=000034



ここで、Rは水素と結合した陰イオン性基であり、R1はOH、OCOH、OCO(CH2)hCH3または作用基であり、hは0以上の整数であり、R2はH、OH、OCOH、OCO(CH2)iCH3または作用基であり、iは0以上の整数であり、R3はOH、SO3Hまたは作用基であり、R4はOH、SO3<

  13  JP2012087120
SUNTORY HOLDINGS LTD;
       PROBLEM TO BE SOLVED: To provide a new compound causing an oral cavity stimulation such as acridness.SOLUTION: There is provided a sugar derivative having a specific structure. The compound has the same skeleton as a chemical structure of a known biophylactic substance called hordatine and having an antifungal property and added with maltose or glucose at a phenolic hydroxy group with a β glycosidic linkage. Such compound is an oral cavity stimulating substance and, by applying the compound to various foods and drinks as an additive or the like, oral cavity stimulation especially a flavor called acridness is newly added or enriched and the foods and drinks can be added with deep flavor, and have satisfactory eat feeling and drink feeling.

  14  JP2012067013
HAYASHIBARA BIOCHEM LAB INC;
       PROBLEM TO BE SOLVED: To provide a powder containing anhydrous crystals of ascorbic acid 2-glucoside, the powder being significantly less prone to caking than existing general-purpose quasi-drug-class powders containing anhydrous crystals of ascorbic acid 2-glucoside, to provide a method for producing the same, and to provide uses thereof.SOLUTION: There are provided a powder containing anhydrous crystals of ascorbic acid 2-glucoside, which contains, in terms of anhydride content, greater than 98.0 mass% and less than 99.9 mass% of ascorbic acid 2-glucoside, and in which the crystallinity of the anhydrous crystals of ascorbic acid 2-glucoside is at least 90%, as calculated on the basis of a powder X-ray diffraction profile, or after free moisture has been removed from the provided powder

  15  JP2011178757
INST NOGUCHI
       PROBLEM TO BE SOLVED: To provide a novel O-mannose sugar chain probe having an O-mannose sugar chain as a partial structure. ; SOLUTION: The O-mannose sugar chain probe includes an alkyl chain having in its terminal an amino group, a salt of an amino group, an azido group or a thiol group, bonded to the reducing terminal of the O-mannose sugar chain via an oligoethylene glycol chain. More specifically, the O-mannose sugar chain probe is represented by formula (1). There is also provided a sugar chain-presenting material obtained by immobilizing the sugar chain probe on a support. ; COPYRIGHT: (C)2011,JPO&INPIT

  16  WO2011096374
NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY;
       (EN) Provided is a novel iodobenzyl-bleomycin compound. Also provided are metal complexes that consist of the iodobenzyl-bleomycin compound and various metal atoms, such as an iodobenzyl-Co-bleomycin compound, that can accumulate on malignant tumors, and that have improved biological characteristics in terms of accumulability on malignant tumors compared to conventional compounds. Also provided are methods for synthesizing the iodobenzyl-bleomycin compound and the metal complexes of the iodobenzyl-bleomycin compound and various metal atoms. The novel iodobenzyl-bleomycin compound is synthesized by adding, to a terminal amino group of bleomycin, iodobenzyl iodide synthesized by using iodobenzyl alcohol and iodine as starting materials.(JA)  新規なヨードベンジル-ブレオマイシン化合物を提供する。また、ヨードベンジル-ブレオマイシン化合物と

  17  WO2011058245
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE;
       (EN) The present invention relates to mannopyranoside-derived compounds and to the use thereof as medicaments, in particular in the treatment of cancer diseases, and also to the method for preparing same and to pharmaceutical compositions comprising such compounds. Medical devices surface-treated with mannopyranoside-derived compounds according to the invention also form part of the invention.(FR) La présente invention est relative à des composés dérivés de mannopyranoside et à leur utilisation à titre de médicaments, notamment pour le traitement de maladies cancéreuses, ainsi qu'à leur procédé de préparation et à des compositions pharmaceutiques comprenant de tels composés. Font également partis de l'invention des dispositifs médicaux traités en surface par des composés dérivés de mannop

  18  WO2011058661
KINJIRUSHI CO., LTD.;
       (EN) Provided is a method for extracting isosaponarin at a high concentration from wasabi (Wasabia japonica) leaves. Also provided is a method for extracting a material for foods, drugs and cosmetics. Isosaponarin is extracted at a high concentration from wasabi leaves, said wasabi leaves being restricted to wasabi leaves having a small leaf size of, for example, 3-14 cm in the maximum leaf width in the direction perpendicular to the leaf stem and also restricted to upland-cultivated wasabi leaves, with aqueous ethanol or 1,3-butylene glycol, thereby providing foods, drugs and cosmetics containing isosaponarin at a high concentration.(JA)  ワサビ葉からイソサポナリンを高濃度で抽出する方法を提供し、さらに食品・医薬品・化粧品素材の抽出方法を提供する。 ワサビ葉のサイズを小面積、例えば3cm~14cmの範囲のものを限定して用い、ワサビ葉は畑栽培ものを限定して用い、さらにワサビ葉を含水エタノールまたは1,3-ブチレングリコールで抽出することに

  19  WO2011038313
REGENTS OF THE UNIVERSITY OF MICHIGAN
LI, SHENGYING
SHERMAN, DAVID, H.
MONTGOMERY, JOHN
CHAULAGAIN, MANI, RAJ
KNAUFF, ALLISON, R.
       The present invention provides regio- and stereoselective oxidation of unactivated C-H bonds using an engineered mutant cytochrome P450 monooxygenase and an engineered substrate.

  20  WO2011038356
JOHNS HOPKINS UNIVERSITY
INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN
LEE, REIKO, TAKASAKA
LEE, YUAN-CHUAN
WANG, MEI-HUI
LIN, WUU-JYH
       This invention provides novel liver targeting agents and their synthetic methods. A liver targeting agent, with a lysine based nitrilo triacetic acid structure as backbone which acquires multivalency with saccharide groups, to bind with a galactosamine chain or lactose chain is disclosed. In particular, only one amino acid L-lysine is involved to provide trivalency. All carboxyl groups in Nε-benzyloxycarbonyl-Nα-dicarboxymethyl-L-lysine can be conjugated with three glycosides of ahGalNAc or ahLac in one step. This invention also provides a hexa-lactoside. In particular, the TFA- AH A- Asp was used to conjugate 2 moles of NTA(ahLac)3. This invention also provides a method for adding a spacer between NTA and DTPA. The extended hepatocyte-specific glyco-ligand has higher 111In-radiolabelling

EGEN, INC.
       Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.

  22  WO2010113960
CCI CORPORATION
MURASE, HIRONOBU
TOMO, TADASHI
       (EN) Disclosed are: a thickening-inhibiting agent for inhibiting thickening of the peritoneal membrane by which thickening of the peritoneal membrane can be inhibited, prevented or treated with relieved side effects; and a dialysis solution which contains this thickening-inhibiting agent.Specifically disclosed are: an agent for inhibiting thickening of the peritoneal membrane, which contains, as the active ingredient, a chromanol glycoside represented by chemical formula (1); and a dialysis solution containing the same. In chemical formula (1), R1, R2, R3 and R4 are either the same or different and each represents a hydrogen atom or a lower alkyl group; R5 represents a hydrogen atom, a lower alkyl group or a lower acyl group; X represents a monosaccharide residue or an oligosaccharide res

  23  WO2010093752
DOW AGROSCIENCES LLC
       The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the structure (I) is disclosed.

THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF
OREGON STATE UNIVERSITY
       This disclosure relates to validamycin A biosynthesis and in particular, to methods of producing validamycin A analogs and uses thereof. In a particular example, a method for making a validamycin A analog includes transforming a host cell with one or more recombinant DNA vectors to produce a valN-inactivated mutant; and culturing the valN-inactivated mutant in a culture medium to produce a validamycin A analog, such as 1,1'-bis-valienamine and validienamycin, and their conversion to valienamine. The present disclosure further relates to compositions including such compounds as well as methods of using the compositions, such as for antifungal agents.

  25  US7737129
EISAI R & D MANAGEMENT CO., LTD.
       Novel substituted liposaccharides useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock and methods of using these agents are provided. Also provided are methods of preparing these agents and intermediates useful therein.

  26  US7718782
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE
N/A(
       A sophorolid produced by a method involving reacting a compound of formula I ##STR00001## with a compound of formula II ##STR00002## wherein R1 and R2 are H, C1-C18 alkyl, C3-C18 alkenyl, C3-C10 cycloalkyl, phenyl, or C1 through C18 acyl or alkoxycarbonyl, R1 and R2 are not both acyl, R3 is H, CH3, CH2-phenyl, CH2--C6H4--OH, CH2CO2H, CH2CH2CO2H, CH(CH3)2, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2OH, CH(CH3)OH, CH2CH2CH

RANBAXY LABORATORIES LIMITED INC. GURGAON, HARYANA IN
       The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases, for example, bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. The present invention also relates to pharmacological compositions containing these monosaccharide derivatives, as well as methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or auto immune disorders.

SNU R&DB FOUNDATION SEOUL KR
       The present invention relates to a fluorescent dye-labeled glucose analog, and a synthesis method and usage of the same, and more particularly, to novel glucose and anomers in which a fluorescent dye is labeled by O-1-glycosylation, an asymmetric synthesis method of the anomers, a molecular bioimaging method of the anomers, and a screening method of curing or preventing drugs for diseases related to glucose metabolism.

SNU R&DB FOUNDATION SEOUL KR
       Disclosed are novel -galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation methods thereof, and pharmaceutical compositions for use in an immune adjuvant containing the same as an active ingredient. The derivatives, in which the amide moiety of -GalCer is bioisosterically replaced with a triazole moiety, direct cytokine secretion toward IL-4 rather than IFN- and thus can be used as a therapeutic for autoimmune diseases regulated by IL-4, such as type 1 diabetes and multiple sclerosis.

  30  US7683163
INDENA S.P.A.
       The present invention relates to colchicine derivatives, in particular to the 3-demethyl and 3-demethylthio-colchicine of the general formula (I) in which X is oxygen or sulfur, a method for the preparation thereof and pharmaceutical compositions containing them. The compounds of formula (I) have muscle relaxing, anti-inflammatory and anti-gout activity. ##STR00001##

RIKEN
       The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, ##STR00001##wherein each symbol is as defined in the specification.

  32  JP2010051243
SANSHO CO
       PROBLEM TO BE SOLVED: To provide an Actinomyces strain which can produce a Rosamicin derivative in which Mycinose is added at C-23 position of a lactone ring of a Rosamicin-like 16-membered macrolide, and a method for producing Rosamicin derivatives using the same. ;
SOLUTION: The Actinomyces strain is obtained by introducing Mycinose biosynthesis gene into an Actinomyces strain which can produce Rosamicin-like 16-membered macrolide, and can produce a Rosamicin derivative in which Mycinose is added at C-23 position of a lactone ring of a Rosamicin. ;

ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM
       The present invention is in the field of Fabry disease and concerns a pathogenic factor allowing diagnosis of Fabry disease. In particular lyso-ceramide trihexosamide (lyso-CTH) has been found to function as a diagnostic marker for Fabry disease.

  34  US7655251
TS PHARMA
UNIVERSITE D'AVIGNON ET DES PAYS DU VAUCLUSE
       Novel compounds, derivatives of -C-phenyl N-tert-butyl nitrone, a method for production and use thereof for the preparation of medicaments for the prevention of treatment of diseases related to oxidative stress.

WONG;
       The present disclosure relates to synthetic alpha-galactosyl ceramide (.alpha.-GalCer) analogs, and their use as immunotherapies. In one aspect. a method of activating a cytokine response in a subject includes administering an effective amount of a compound to a subject, wherein the subject has an adaptive immune system that includes a population of cells, the population including at least one lymphocyte and at least one antigen-presenting cell, and wherein the compound is represented by the structure of formula 1: ##STR00001## or a pharmaceutically acceptable salt thereof; forming a complex between the compound and the antigen-presenting cell, wherein the formation of the complex results in the activation of a receptor on the lymphocyte; and activating the lymphocyte to produce the cytok

ALNYLAM PHARMACEUTICALS, INC.
       One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moi

  37  US7632930
SANKYO COMPANY LIMITED
       Compounds having the formula (I): ##STR00001## wherein A represents a group such as a cyclic group, R1 and R2 represent groups such as alkyl groups or hydroxymethyl groups, and n represents 1 or 2, or pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof have superior activity and stability, and are useful for the treatment and/or prevention of diabetes mellitus, or the like.

TS PHARMA
UNIVERSITE D'AVIGNON ET DESPAYS DU VAUCLUSE
       Compounds derived from .alpha.-C-phenyl-N-tert-butylnitrone, a process for the preparation thereof and use thereof for the preparation of medicaments for use in preventing or treating oxidative stress-related diseases.

PETTIT;
       Described herein are novel cerebroside compounds, designated as Turbostatin 1, Turbostatin 2, Turbostatin 3, and Turbostatin 4. These compounds were extracted and isolated from the marine mollusk Turbo stenogyrus, and their structures elucidated. The new compounds exhibit significant cancer cell growth inhibition activity against a variety of murine and human cancer cell lines, and as such appear will be useful in the treatment of various forms of neoplastic disease.

NIPPON SHINYAKU CO., LTD.
       The object of the present invention is to provide a novel and useful galactose derivative, which is a component of a drug carrier by which a medicine can be efficiently transferred into the liver, a drug carrier comprising the derivative, and a pharmaceutical composition comprising the drug carrier and a medicine.The present invention relates to a galactose derivative represented by the following general formula (I) a drug carrier comprising the derivative and a cationic lipid, and a pharmaceutical composition comprising the carrier and a medicine (preferably a double-stranded RNA, a double-stranded DNA, an oligo nucleic acid). ##STR00001## wherein, R1 represents hydrogen, an alkyl having 1 to 10 carbons which may be substituted or 1-(D)-deoxylactito-1-yl; R2 represe

  41  JP2009268384
HIROSAKI UNIV
       PROBLEM TO BE SOLVED: To provide a method for constructing a sugar chain useful for preparation etc., of artificial proteoglycans or artificial glycosaminoglycans. ;
SOLUTION: The method for constructing the sugar chain is characterized by carrying out oxymercuration of an unsaturated bond in an unsaturated hexuronic acid of an oligosaccharide having the unsaturated hexuronic acid at the nonreducing terminal (with the proviso that a mercury salt to be used is 5 molar equivalents at the maximum based on the oligosaccharide), and the subsequent reductive demercuration, thereby converting the unsaturated hexuronic acid at the nonreducing terminal into hexuronic acid, and then conducting glycosylation of the hexuronic acid. Thereby, a new methodology for extending the sugar chain by c

SUGIMOTO;
       [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria.[Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae, erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

CERUNDOLO;
       There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C' channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A' channel of human CDId, such that R1 fills at least at least 30% of the occupied volume of the C' channel compared to the volume occupied by the terminal nC14H29 of the sphingosine chain of .alpha.-galactosylceramide when bound to human CDId and R2 fills at least 30% of the occupied volume of the A' channel compared to the volume occupied by the terminal nC25H51 of the acyl chain of .alpha.-galactosylceramide when bound to human CDId R3 represents hydrogen or OH, Ra and Rb each r

THE ROCKEFELLER UNIVERSITY
THE SCRIPPS RESEARCH INSTITUTE
       This invention relates to immunogenic compounds which may serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.

SUZUKI;
       A method is provided in which the recognition specificity of a virus for a receptor sugar chain can be easily determined with a simple instrument or apparatus. This method for determining the recognition specificity of a virus for a receptor sugar chain or for determining the change in a host infected in accordance with the mutation of virus includes the steps of bringing a sample of the virus into contact with a support having a polymer with sialo-oligosaccharide immobilized on the surface thereof; and assaying the degree of binding therein to determine the recognition specificity of the virus for the receptor sugar chain and to determine the change in a host range. The method is suitable for the surveillance of a virus.

TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD.
       A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.

RANBAXY LABORATORIES LIMITED INC.
       The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases, for example, bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. The present invention also relates to pharmacological compositions containing these monosaccharide derivatives, as well as methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or auto immune disorders.

MIYAKE;
       A therapeutic drug for diseases, in which NKT cells or stimulus of NKT cells is involved in deterioration of disease conditions, containing, as an active ingredient, a glycolipid derivative having the formula (I): ##STR00001##wherein R1 indicates an aldopyranose residue, R2 indicates a hydrogen atom or a hydroxy group, A indicates --CH2--, --CH(OH)--CH2-- or --CH.dbd.CHCH2--, x indicates an integer of 13 to 16 and y indicates an integer of 0 to 25 or its pharmacologically acceptable hydrate or solvate.

SAVAGE;
       Modified glycolipid compounds are provided. Also disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, and methods suitable for labeling NKT cells.

NITROMED, INC.
       The invention describes novel organic nitric oxide donor salts of a antimicrobial compounds, and novel compositions and kits comprising at least one organic nitric oxide donor salt of an antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. In one embodiment the antimicrobial compounds of the invention are aztreonam, ciprofloxacin, doripenam, duramycin and tobramycin. The organic nitric oxide donors that form salts are preferably organic nitrates, organic nitrites, nitrosothiols, thionitrites and heterocyclic nitric oxide donors. The heterocyclic nitric oxid

  检索记录:  420  总页数:  9  当前页码: 1      每页条数:  50 100 200   9 3 4 :      返回

日本专利